Legal & General Group
KYMR icon

Legal & General Group’s Kymera Therapeutics KYMR Stock Holding History

Legal & General Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.06M Sell
36,734
-6,694
-15% -$530K ﹤0.01% 1736
2025
Q4 		$3.38M Sell
43,428
-69
-0.2% -$4.66K ﹤0.01% 1767
2025
Q3 		$2.46M Buy
43,497
+1,974
+5% +$89K ﹤0.01% 1891
2025
Q2 		$1.81M Buy
41,523
+1,486
+4% +$51.2K ﹤0.01% 2005
2025
Q1 		$1.1M Sell
40,037
-10
-0% -$365 ﹤0.01% 2158
2024
Q4 		$1.61M Buy
40,047
+2,818
+8% +$127K ﹤0.01% 2071
2024
Q3 		$1.76M Sell
37,229
-7,259
-16% -$321K ﹤0.01% 2034
2024
Q2 		$1.33M Buy
44,488
+2,003
+5% +$69.3K ﹤0.01% 2101
2024
Q1 		$1.71M Buy
42,485
+4,095
+11% +$147K ﹤0.01% 1999
2023
Q4 		$977K Buy
38,390
+7,382
+24% +$132K ﹤0.01% 2221
2023
Q3 		$431K Sell
31,008
-254
-0.8% -$5.11K ﹤0.01% 2492
2023
Q2 		$719K Sell
31,262
-3,753
-11% -$108K ﹤0.01% 2336
2023
Q1 		$1.04M Buy
35,015
+1,861
+6% +$60K ﹤0.01% 2139
2022
Q4 		$828K Buy
33,154
+424
+1% +$11.3K ﹤0.01% 2201
2022
Q3 		$713K Buy
32,730
+4,027
+14% +$106K ﹤0.01% 2250
2022
Q2 		$565K Buy
28,703
+258
+0.9% +$6.03K ﹤0.01% 2311
2022
Q1 		$1.2M Buy
28,445
+14,745
+108% +$623K ﹤0.01% 2178
2021
Q4 		$870K Buy
13,700
+305
+2% +$17.8K ﹤0.01% 2266
2021
Q3 		$787K Buy
13,395
+6,717
+101% +$389K ﹤0.01% 2303
2021
Q2 		$324K Buy
6,678
+4,956
+288% +$215K ﹤0.01% 2422
2021
Q1 		$67K Sell
1,722
-24
-1% -$1.45K ﹤0.01% 2737
2020
Q4 		$109K Buy
+1,746
New +$85.2K ﹤0.01% 2564

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Legal & General Group's KYMR Position: Q1 2026 in Review

Legal & General Group reduced its Kymera Therapeutics (KYMR) stake by 15% in Q1 2026, selling an estimated $530K and leaving 36,734 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1736.

Legal & General Group first reported a position in KYMR in Q4 2020 and has held it in 22 quarters since. The position peaked at $3.38M in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Legal & General Group held 36,734 shares of Kymera Therapeutics worth $3.06M as of Q1 2026.
  • Legal & General Group sold 6,694 Kymera Therapeutics shares in Q1 2026, an estimated $530K.
  • Kymera Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1736 holding.
  • Legal & General Group first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Legal & General Group's Kymera Therapeutics position peaked at $3.38M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.